IL10 and neoplasm: In a multi-variant analysis, IgG4 positivity (p = 0.001; HR = 3.366; 95% CI 1.607–7.050), tumor IL-10 (p = 0.000; HR = 7.195; 95% CI 2.418–21.411) and tumor stage and tumor stage (p = 0.000; HR = 1.442; 95% CI 1.0247–1.667) were independently associated with a shorter RFS.